PD-L1 interacts with the programmed cell death 1 (PD-1) receptor on T cells to induce T-cell exhaustion [1], and the monoclonal antibody therapy blocks this inhibitory interaction to re-activate T-cell-mediated tumor killing. The gene discussed is PDCD1; the disease is neoplasm.